Cyclic pamidronate infusion for neonatal-onset osteogenesis imperfecta

Area of Science:

• Pediatric Orthopedics
• Medical Genetics
• Pharmacology

Background:

• Severe osteogenesis imperfecta (OI) presents with low bone mass, frequent fractures, and pain from birth, leading to a poor prognosis.
• Neonatal OI significantly impacts infant health and development, necessitating early intervention strategies.

Purpose of the Study:

• To evaluate the efficacy of early cyclic pamidronate treatment in infants with severe osteogenesis imperfecta.
• To assess the long-term outcomes, including bone mineral density, fracture rates, and functional status, in patients treated before one year of age.

Main Methods:

• Six infants with severe OI, experiencing fractures in utero or within the first month of life, received cyclic pamidronate infusions starting at a mean age of 2.8 months.
• Treatment involved regular pamidronate infusions, with outcomes monitored for bone mineral density, fracture incidence, and functional development.

Main Results:

• Patients tolerated treatment, with transient hypocalcemia as the primary side effect during the first infusion.
• Improvements in irritability and feeding were noted within 2-3 months post-infusion.
• Significant increases in bone mineral density were observed over the first two years, with a fracture rate of 0.6 per year. At a mean age of 6.4 years, five patients achieved normal ambulatory function, though they remained shorter than average.

Conclusions:

• Early initiation of cyclic pamidronate therapy in neonatal osteogenesis imperfecta can lead to favorable clinical outcomes.
• Timely treatment is crucial for improving bone health and functional abilities in infants with severe OI.